Engichem Life Sciences Pursues Development of Health Functional Foods Specialized in Metabolic Health

Leveraging EC-18-Based Immune and Inflammation Regulation Research
Developing Product Line Targeting Demand for Chronic Metabolic Disease Management, Including Diabetes

Engichem Life Sciences is set to expand its health functional food business, leveraging its experience in immune and inflammation regulation research.

Engchem Life Sciences company logo image. Engchem Life Sciences

On June 12, Engichem Life Sciences announced that it is pursuing the development of health functional foods specializing in metabolic health, utilizing its proprietary immune and inflammation regulation technology accumulated during the research of its independently developed new drug candidate, "EC-18."

The company’s strategy is to continue new drug development—such as its next-generation DAC anticancer platform based on PROTAC—while simultaneously expanding its portfolio of health management products.

The products under development primarily target consumers seeking solutions for the management of chronic metabolic diseases, such as diabetes. Engichem Life Sciences explained that the products have been designed with a focus on immune balance and inflammation management needs, with particular attention paid to improving the bitter taste—a common drawback of conventional diabetes-related health foods.

According to the company, product design has been completed and prototypes have already been produced. Moving forward, Engichem Life Sciences plans to gradually review raw material combinations and formulations, the scope of functional claims, production stability, and distribution strategies to advance commercialization.

Choi Kyungseok, Vice President of Engichem Life Sciences, stated, “We are confirming the potential to extend our research experience in immune regulation and inflammation response, based on EC-18, to a lineup of health management products.” He added, “We are currently developing health functional foods with improved taste and consumption convenience, targeting consumers with metabolic health management needs.” He continued, “We will thoroughly review functional ingredients, production quality control, and standards for labeling and advertising to evolve this into a comprehensive healthcare business model.”

Moving forward, Engichem Life Sciences plans to continue its research and development based on EC-18 and the development of next-generation new drug platforms, while also exploring the potential for expanding into health functional foods and healthcare product lines.

This content was produced with the assistance of AI translation services.